Durvalumab vs Mirvetuximab Soravtansine

## Durvalumab vs Mirvetuximab Soravtansine: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Mirvetuximab Soravtansine**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Mirvetuximab Soravtansine — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Mirvetuximab Soravtansine — Antibody drug conjugate.